ERBB2 and breast cancer: These results suggested that blocking ER-α36 expression or the activity of EGFR/HER-2, or their downstream signaling MAPK/ERK could destroy ER-α36-mediated nongenomic estrogen signaling and thereby increase cisplatin sensitivity in breast cancer cells.